Original language | English |
---|---|
Pages (from-to) | 617-619 |
Number of pages | 3 |
Journal | Current Opinion in Urology |
Volume | 30 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1 Jul 2020 |
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer
Edmond M. Kwan, Arun A. Azad
Research output: Contribution to journal › Article › Other › peer-review
1
Citation
(Scopus)